Mukka Proteins Limited Q1 FY27 results deck summary

Results deck of 13 Aug 2026, summarised by AI from the filing.

Management targets revenue of ₹3,000+ cr by FY30, more than 2x growth in ~4 years.

Key takeaways

1. FY30 target Management targets revenue of ₹3,000+ cr by FY30, more than 2x growth in ~4 years.
2. Delta Marine Acquired 51% stake in Delta Marine Products for ₹11.1 crore, strengthening fish meal and fish oil manufacturing.

Original filing on BSE

Mukka Proteins Limited Q1 FY27 results

As filed: Revenue ₹490 cr (+186% year on year), EBITDA ₹48.0 cr (+243% year on year), PAT ₹18.6 cr (+300% year on year), EBITDA margin 9.8% (+161 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹381 cr (0% year on year), EBITDA ₹33.9 cr (+17% year on year), PAT ₹21.4 cr (+53% year on year), EBITDA margin 8.9% (+131 bps). Score 34 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 131 bps year on year. Other income 53% of PBT. Revenue fell 42% from last quarter. Share price after the results: −3.2% in 28 days (Nifty 500: +0.3%).
• Q3 FY26: Revenue ₹654 cr (+116% year on year), EBITDA ₹45.4 cr (+11% year on year), PAT ₹27.3 cr (+1% year on year), EBITDA margin 7.0% (−658 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 658 bps year on year. Share price after the results: −14.1% in 29 days (Nifty 500: −9.6%).
• Q2 FY26: Revenue ₹245 cr (+64% year on year), EBITDA ₹21.0 cr (+110% year on year), PAT ₹7.0 cr (+300% year on year), EBITDA margin 8.6% (+186 bps). Score 89 of 100, Above trend. EBITDA margin rose 186 bps year on year. Other income 60% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: −2.5% in 30 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹171 cr (−1% year on year), EBITDA ₹14.0 cr (0% year on year), PAT ₹2.0 cr (−60% year on year), EBITDA margin 8.2% (+9 bps). Score 11 of 100, Below trend. EBITDA margin was flat year on year. Other income 100% of PBT. Consolidated profit -60% but standalone +0%. Not enough history for a trend yet: scored on growth alone. Revenue fell 55% from last quarter. Share price after the results: −1.1% in 30 days (Nifty 500: +2.2%).
• Q4 FY25: Revenue ₹382 cr (+49% year on year), EBITDA ₹29.0 cr (−9% year on year), PAT ₹14.0 cr (−52% year on year), EBITDA margin 7.6% (−486 bps). Score 41 of 100, In line with trend. EBITDA margin fell 486 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 48% from last quarter. Share price after the results: −2.1% in 29 days (Nifty 500: +0.5%).
• Q3 FY25: Revenue ₹303 cr (−41% year on year), EBITDA ₹41.0 cr (+116% year on year), PAT ₹27.0 cr (+125% year on year), EBITDA margin 13.5% (+986 bps). Score 65 of 100, Above trend. EBITDA margin rose 986 bps year on year. Not enough history for a trend yet: scored on growth alone.
• Q2 FY25: Revenue ₹126 cr, EBITDA ₹8.0 cr, PAT ₹2.0 cr, EBITDA margin 6.4%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Mukka Proteins Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (13 Aug 2026)
• Q4 FY26: Results deck (22 May 2026)
• Q3 FY26: Results deck (13 Feb 2026)